Immune Thrombocytopenia Management in Adults
Immune Thrombocytopenia Purpura
About this trial
This is an interventional treatment trial for Immune Thrombocytopenia Purpura focused on measuring Primary Immune Thrombocytopenia, Etrombopag, Dexamethasone, Romiplostim, Rituximab, Autoimmune Disorder
Eligibility Criteria
Inclusion Criteria: Inclusion criteria were adult patients aged 18 years or older, diagnosed with primary ITP after excluding secondary causes and with an initial PLTs count of less than 30 ×109/L or with hemorrhage manifestations. Exclusion Criteria: Patients with a confirmed secondary ITP diagnoses such as (chemicals induced, systemic lupus erythematosus, immune thyroid diseases, a lymphoproliferative disease, or chronic infection, such as Helicobacter pylori, human immunodeficiency virus (HIV) or hepatitis C virus (HCV); with cardiac, renal, or liver disease; who had received NSAIDs or anti-platelets within one month before the initiation of the enrollment were excluded from the study.
Sites / Locations
- EL-Kasr elineiyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Active Comparator
Experimental
Experimental
Experimental
Experimental
Control group
PSL - AZA group
The RTX group
The ELTRO group
The ROMP group
The first (control )group includes patients with confirmed diagnosed who received IV pulse (High Dose-Dexamethasone) therapy
The second group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy
The third group includes patients with confirmed diagnosed who received Prednisolone -Azathioprine therapy
The fourth group includes patients with confirmed diagnosed who received E therapy
The fifth group includes patients with confirmed diagnosed who received Romiplostim therapy